Printer Friendly

THERMASCAN PREPARES TO FILE IND WITH FDA FOR FLUOROGNOST HIV-2 IFA

 THERMASCAN PREPARES TO FILE IND WITH FDA FOR FLUOROGNOST HIV-2 IFA
 SOUTHAMPTON, N.Y., Oct. 7 /PRNewswire/ -- Thermascan, Inc. announced today that it is preparing to file an IND with the Food and Drug Administration for Fluorognost HIV-2 IFA as a screening and confirmatory test, which is used to detect antibodies to Human Immunodeficiency Virus Type 2 (HIV-2) in human blood serum or plasma. HIV-2 is a virus that causes AIDS-related symptoms. Fluorognost HIV-2 utilizes the same format as the FDA-approved Fluorognost HIV-1 IFA.
 There is no approved confirmatory test available for detecting the presence of human immunodeficiency virus type 2, although there are a number of assays currently under investigation.
 Thermascan further announces that after IND approval from the Food and Drug Administration, clinical studies will be conducted in cooperation with the Centers for Disease Control (CDC) in Atlanta, the American Red Cross in Washington as well as various public health groups in a number of other states.
 In addition, Thermascan indicated that by the end of this year it will also file for FDA approval of a confirmation test for HTLV-1 and HTLV-2 which will utilize the same immunofluorescence assay technology.
 -0- 10/7/92
 /CONTACT: Prof. D. Baurs-Krey, chairman and CEO of Thermascan, 516-287-3739/ CO: Thermascan, Inc. ST: New York IN: HEA SU:


CK-LR -- NY022 -- 7418 10/07/92 11:28 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 7, 1992
Words:225
Previous Article:GOLDRUSH CASINO & MINING CORP. SHARES TRADE OVER THE COUNTER IN NEW YORK
Next Article:ALLIED BANKSHARES THIRD QUARTER NET INCOME PER SHARE INCREASES BY 68 PERCENT; NINE MONTH NET INCOME PER SHARE INCREASES BY 50 PERCENT
Topics:


Related Articles
THERMASCAN STATEMENT ON MERGER PROCEEDINGS
CELL GENESYS ANNOUNCES IND FILING FOR ANTI-HIV T CELL THERAPY
Epimmune Provides HIV Vaccine Program Update.
CytRx Corporation, Advanced BioScience Laboratories and University of Massachusetts Announce Filing of Investigational New Drug Application for...
CytRx Announces Plans for Filing of Investigational New Drug Application for HIV Vaccine and Strategic Alliance With Advanced BioScience Laboratories.
Medical Discoveries Inc. Announces Multiple Clinical Development Priorities Under a Drug Master File.
Medical Discoveries Inc. Files IND With FDA for Cystic Fibrosis.
Bavarian Nordic Initiates Phase I/II Clinical Trials With MVA-BN(R) Polytope Against HIV.
Panacos Pharmaceuticals Files IND for HIV Drug Target.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters